Prescribing of SGLT2 inhibitors in primary care: A qualitative study of General Practitioners and Endocrinologists-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prescribing of SGLT2 inhibitors in primary care: A qualitative study of General Practitioners and Endocrinologists

Published:2021-10 Issue: Volume:180 Page:109036
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Milder Tamara Y.,Stocker Sophie L.,Baysari Melissa,Day Richard O.,Greenfield Jerry R.

Funder

National Heart Foundation of Australia

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference28 articles.

1. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

2. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017

3. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N Engl J Med,2019

4. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy;Perkovic;N Engl J Med,2019

5. Dapagliflozin in patients with heart failure and reduced ejection fraction;McMurray;N Engl J Med,2019

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of, time to, and type of first add‐on anti‐hyperglycaemic therapy to metformin in Australia, 2018–2022;British Journal of Clinical Pharmacology;2024-09-03

2. Geographic variation in sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia;Diabetes, Obesity and Metabolism;2024-04-15

3. Implementing a Sodium-Glucose Cotransporter 2 Inhibitor Module With a Software Tool (Future Health Today): Qualitative Study;JMIR Formative Research;2024-03-13

4. Identifying Barriers and Facilitators for Increasing Uptake of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in British Columbia, Canada, using the Consolidated Framework for Implementation Research;Canadian Journal of Kidney Health and Disease;2023-12-29

5. SGLT2 Inhibitors and Diabetic Kidney Disease: Targeting Multiple and Interrelated Signaling Pathways for Renal Protection;Current Molecular Pharmacology;2023-11-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3